# LeMaitre Vascular Inc. (LMAT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $80.67, market value $1.8 billion.

## Valuation
- **P/E (trailing): 28.2×** (5-yr avg 41.4×, 3-yr avg 40.2×). LeMaitre Vascular Inc. trades at 28.2× trailing earnings, well below its own five-year average of 41.4×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 25.4×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.83**. A PEG of 0.83 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 7.0×**. Each dollar of revenue is priced at 7.0×.
- **Price / book: 4.4×**. The shares trade at 4.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 4.0%** (5-yr avg 2.7%). Free cash flow equals 4.0% of the market value, above its five-year average of 2.7%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 3.5%**. The inverse of the P/E: 3.5% of the price is earned each year.

## Profitability
- **Gross margin: 72.9%**. LeMaitre Vascular Inc. keeps 72.9% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 29.5%**. 29.5% of revenue is left after running the business, an exceptional level.
- **Net margin: 23.1%**. 23.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 14.7%**. 14.7% on shareholders' equity is solid.
- **Return on assets: 10.7%**. Each dollar of assets produces 10.7% of profit.

## Growth
- **Revenue growth (1 yr): 13.5%** (3-yr 15.6%/yr, 5-yr 14.0%/yr). Revenue grew 13.5% over the last year, against 14.0% a year compounded over five years.
- **EPS growth (1 yr): 30.6%** (3-yr 39.4%/yr, 5-yr 19.4%/yr). Earnings per share rose 30.6%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 49.8%/yr**. Free cash flow has compounded at 49.8% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Current ratio: 12.89** (quick 12.89). Current assets cover the next year's liabilities 12.89 times.
- **Altman Z-score: 7.49**. A Z-score of 7.49 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 1.24%** ($0.90 per share, trailing). LeMaitre Vascular Inc. yields 1.24%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 31%** (28% of free cash flow). 31% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 15**. 15 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 16.1%/yr** (1-yr 25.0%). The dividend has compounded at 16.1% a year over five years, doubling roughly every 4 years at that pace.

## Analyst view
- **Analyst consensus: buy** (7 analysts). 7 analysts cover LeMaitre Vascular Inc.; the consensus is buy, with an average price target of $107.00 (+33% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -16.3%** (YTD -0.1%, 3-mo -14.6%). The shares are down 16.3% over twelve months including dividends.
- **From 52-week high: -31.6%** (3.1% above the low). Trading 32% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 39**. An RSI of 39 is neutral.
- **Beta (1 yr): 0.50** (volatility 45%). Beta of 0.50 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LMAT · Page: https://foliofundamentals.com/stocks/lmat

Not investment advice.